Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2020
ReviewReview article: gastrointestinal features in COVID-19 and the possibility of faecal transmission.
There is little published evidence on the gastrointestinal features of COVID-19. ⋯ Gastrointestinal symptoms are common in patients with COVID-19, and had an increased prevalence in the later stage of the recent epidemic in China. SARS-CoV-2 enters gastrointestinal epithelial cells, and the faeces of COVID-19 patients are potentially infectious.
-
Aliment. Pharmacol. Ther. · May 2020
The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent.
Patients with chronic pancreatitis or pancreatic cancer commonly develop exocrine pancreatic insufficiency, and may not be adequately treated with pancreatic enzyme replacement therapy (PERT). ⋯ Testing for exocrine insufficiency, and appropriate dosing of PERT in patients with chronic pancreatitis or pancreatic cancer, is infrequent and inconsistent in an insured US population. Efforts are needed to educate medical providers on the best practices for managing exocrine pancreatic insufficiency in these patients.
-
Aliment. Pharmacol. Ther. · Apr 2020
Meta AnalysisSystematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update.
There is still controversy with regard to the efficacy of individual probiotic strains for the management of acute gastroenteritis. ⋯ In children with acute gastroenteritis, low- to very low-quality evidence suggests that S boulardii confers a benefit for several diarrhoeal outcomes.